Gilead Invests Further in Arcellx, Extends Collaboration
15 Novembro 2023 - 8:58AM
Dow Jones News
By Colin Kellaher
Gilead Sciences is investing another $200 million in
clinical-stage biotechnology company Arcellx as part of an
expansion of the duo's collaboration to include lymphomas.
The companies on Wednesday said Gilead's Kite unit has exercised
its option to negotiate a license for Arcellx's ARC-SparX program,
ACLX-001, in multiple myeloma, and that they are expanding the
scope of the collaboration launched late last year for Arcellx's
CART-ddBCMA to include lymphomas.
Foster City, Calif., biopharmaceutical company Gilead, which
last year made an initial equity investment of $100 million in
Arcellx, will buy another 3.24 million share at $61.68 apiece, a
30% premium to Tuesday's closing price of $47.47 for the
Gaithersburg, Md., company.
Arcellx said the investment, which will boost Gilead's stake to
about 13%, will extend its cash runway into 2027.
Arcellx also will receive an upfront cash payment of $85 million
at closing and will be eligible for potential milestone payments,
the companies said.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 15, 2023 06:43 ET (11:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Arcellx (NASDAQ:ACLX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Arcellx (NASDAQ:ACLX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024